Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Pyrotinib/Neratinib in HER2+ Breast Cancer Brain Mets
NCT06015113Not yet recruiting
- Sponsor
- Xi'an International Medical Center Hospital
- Start
- Sep 2023
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Open-label, single-arm trial of disitamab vedotin in HER2-positive breast cancer, sponsored by Xi'an International Medical Center Hospital. Primary endpoint: Progression-free survival at 100 months. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06015113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015113.